Targeted Apoptotic Pathway Reactivation and Small-Molecule BH3-Mimetics Reshaping Hematologic Oncology
Re-engaging programmed cell death in refractory hematologic malignancies is driving rapid commercial and clinical expansion across small-molecule BH3-mimetic therapeutics. Detailed analysis within the Bcl-2 (B-Cell Lymphoma 2) Inhibitors Market report highlights how selective B-cell lymphoma 2 (Bcl-2) inhibitors (such as venetoclax) bind directly to overexpressed anti-apoptotic proteins....
0 Comments 0 Shares 146 Views 0 Reviews